

(iii) Mechanical equipment

Maintenance of the mechanical equipment is conducted regularly.

(b) Permanent status of three Interim Regional Emergency Government Headquarters

The three existing interim regional emergency government headquarters, situated in less populated provinces, are at various stages of operational readiness, however in a period of international tension, these headquarters could be made operational.

6. Saskatchewan Interim Regional Emergency Government Headquarters

The Saskatchewan interim regional emergency government headquarters is situated in Regina and the location is unacceptable. A new site has been surveyed at Moose Jaw and development plans are under way with the Department of Public Works.

CANADIAN ARMED FORCES—CAREERS IN THE SERVICE

Question No. 1,218—**Mr. Hnatyshyn:**

1. How many military college graduates started careers with the Canadian Armed Forces and remained in the service (a) over (b) under six years?
2. Did the Department of National Defence conduct exit surveys upon separation of military college graduates or subsequent exit surveys and analysis following separation?
3. How many graduates have left the service and for what reason?
4. How many aircrew members have left the service for other flying jobs and how many moved to the United States?

Hon. D. Gilles Lamontagne (Minister of National Defence): 1. Since January 1, 1970:

- (a) 2115;
- (b) 244.

2. No. However, as a matter of policy, all members who request release are required to state in writing the reason for requesting release. All such members are subsequently interviewed by a superior officer and all requests are reviewed at National Defence Headquarters. Special monitoring procedures for military college graduates do not exist. Information concerning the subsequent civilian or foreign employment of released officers is not collected and thus an analysis following separation is impossible.

3. Since January 1, 1970—309

The reasons were as follows:

—on request	259
—not advantageously employable or unsuitable	21
—on medical grounds	18
—death	11

4. Since January 1, 1970—49

Information whether released personnel have obtained other flying jobs is not available. Data whether released aircrew members have moved to the United States is not readily available prior to 1978 and since 1978 no released members are known to have moved there.

ANTURANE

Question No. 1,226—**Mr. Cossitt:**

With reference to the drug with the trade name anturane, generic name sulfapyrazone, used in the treatment of gout, is the Department of National Health and Welfare aware of certain leading American medical opinions that the drug has been found useful in the treatment of myocardial infarction and, that in particular, it assists in preventing further heart attacks and, if so, what are all the details possessed by the department?

Hon. Monique Bégin (Minister of National Health and Welfare): In the issue of the *New England Journal of Medicine* of January 31, 1980, an article appeared in which it was concluded that the drug Anturan—Ciba Geigy (generic name—sulfapyrazone), was responsible for a marked reduction in sudden death in patients during the critical first six months following their first heart attack (myocardial infarct). The manufacturer approached the United States' Food and Drug Administration (FDA) for permission to use this claim in advertising and labelling. After analysing the individual case report, the FDA refused permission on the basis that there was no statistically significant difference between treated and untreated patient groups in the number of sudden deaths, when the groupings were carefully separated on the basis of the nature of the deaths. In Canada, Anturan has been sold for many years for the treatment of gout. In recent years, the health protection branch of the Department of National Health and Welfare, on the basis of satisfactory submissions of data, has permitted claims for Anturan in diseases associated with abnormal blood clotting. The manufacturer has never approached the department for acceptance of the sudden death claim. Should the manufacturer do so, officers of the Department of National Health and Welfare would then examine the individual case histories and apply appropriate statistical analyses.

GEROVITAL H3

Question No. 1,227—**Mr. Cossitt:**

1. Is the Department of National Health and Welfare aware of a medicine known as Gerovital H-3 reported to be useful with regard to the effects of aging and a wide range of other ailments and, if so, have experiments been carried out in Canada on this medicine?
2. To the knowledge of the department, is it (a) distributed free in Roumania to everyone over 45 years of age (b) being produced in the State of Nevada (c) will it be permitted for use in Canada and, if so, on what date?
3. To the knowledge of the government, did a number of noted world figures who lived a lengthy lifespan take the drug?
4. Has the department studied the medicine and, if so, what were the results?

Hon. Monique Bégin (Minister of National Health and Welfare): 1. Yes. Gerovital H3 is a pharmaceutical product containing procaine, a well-known local anaesthetic. Clinical